ADMP on NASDAQ

Adamis Pharmaceuticals Corporation

Pharmaceutical company in San Diego, United States.1

Price unavailable

Last updated Oct 16, 2026.

Overview

2006Founded1

Compare with PureTech Ventures, SPRUCE BIOSCIENCES, INC. or InMed Pharmaceuticals Inc., or pick any stock.

  • TickerADMP on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego1
  • Websitewww.adamispharmaceuticals.com
  • Incorporated inDE3
  • Business address11682 El Camino Real, Suite 300, San Diego, Ca 921303
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-30.1%Gross margin4
-526.9%Operating margin4
-556.7%Net margin4
115.3%Revenue growth, 20224
-$26.6MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue21¢$6.2M
  • Research and development35¢$10.4M
  • Selling, general and admin44¢$13.2M
  • Income tax0¢$2.0K

Out of $4.8M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$4.8M in 2022−27% since 2016
0$10.0M$20.0M$30.0M2016: $6.5M$6.5M20162017: $13.1M$13.1M2017+102%2018: $15.1M$15.1M2018+15%2019: $22.1M$22.1M2019+47%2020: $16.5M$16.5M2020−25%2021: $2.2M$2.2M2021−87%2022: $4.8M$4.8M2022+115%
Gross profit9678104-$1.4M in 2022
-$5.0M0$5.0M$10.0M2016: $1.6M$1.6M20162017: $5.7M$5.7M2017+249%2018: $5.3M$5.3M2018−6%2019: $6.6M$6.6M2019+25%2020: -$3.6M-$3.6M20202021: -$4.7M-$4.7M2021+31%2022: -$1.4M-$1.4M2022−69%
Operating income9678104-$25.1M in 2022−1% since 2016
-$40.0M-$30.0M-$20.0M-$10.0M02016: -$25.2M-$25.2M20162017: -$24.8M-$24.8M2017−2%2018: -$39.5M-$39.5M2018+59%2019: -$29.4M-$29.4M2019−26%2020: -$36.3M-$36.3M2020+24%2021: -$32.1M-$32.1M2021−12%2022: -$25.1M-$25.1M2022−22%
Net income9678104-$26.5M in 2022+36% since 2016
-$60.0M-$40.0M-$20.0M02016: -$19.4M-$19.4M20162017: -$25.5M-$25.5M2017+31%2018: -$39.0M-$39.0M2018+53%2019: -$27.5M-$27.5M2019−29%2020: -$49.4M-$49.4M2020+80%2021: -$45.8M-$45.8M2021−7%2022: -$26.5M-$26.5M2022−42%
Fiscal year2016201720182019202020212022
Revenue$6.5M5$13.1M6$15.1M7$22.1M8$16.5M8$2.2M4$4.8M4
Cost of revenue$4.9M9$7.4M6$9.8M7$15.5M8$6.3M10$6.9M4$6.2M4
Gross profit$1.6M9$5.7M6$5.3M7$6.6M8-$3.6M10-$4.7M4-$1.4M4
Research and development$9.7M9$7.5M6$18.8M7$10.4M8$8.0M10$11.3M4$10.4M4
Selling, general and admin$17.1M9$22.8M6$25.9M7$25.3M8$20.1M10$16.1M4$13.2M4
Operating income-$25.2M9-$24.8M6-$39.5M7-$29.4M8-$36.3M10-$32.1M4-$25.1M4
Interest$214.4K9$231.3K6$157.8K7$123.3K8$4.9K10$6.6K10
Income tax-$4.6M9-$339.4K6-$369.3K7$8.7K8$2.4K10$7964$2.0K4
Net income-$19.4M9-$25.5M6-$39.0M7-$27.5M8-$49.4M10-$45.8M4-$26.5M4
Earnings per share-$1.195-$0.324-$0.184
Earnings per share (diluted)-$1.195-$0.324-$0.184

Compare Adamis Pharmaceuticals Corporation with another company

Former names

  • Adamis Pharmaceuticals CorpApr 8, 2009 to Sep 1, 20233
  • CELLEGY PHARMACEUTICALS INCJul 9, 1996 to Apr 3, 20093

Timeline

  1. 2006Founded Founded1

Recent filings

  1. Jul 1, 20248-K CURRENT REPORT
  2. Feb 7, 20248-K CURRENT REPORT
  3. Feb 5, 20248-K CURRENT REPORT
  4. Jan 31, 20248-K CURRENT REPORT
  5. Jan 23, 20248-K CURRENT REPORT
  6. Jan 3, 20248-K CURRENT REPORT
  7. Jan 3, 20248-K CURRENT REPORT
  8. Dec 21, 20238-K CURRENT REPORT
  9. Dec 4, 20238-K CURRENT REPORT
  10. Nov 28, 20238-K CURRENT REPORT
  11. Nov 15, 20238-K CURRENT REPORT
  12. Nov 14, 202310-Q QUARTERLY REPORT
  13. Nov 14, 20238-K CURRENT REPORT
  14. Nov 2, 20233 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
  15. Nov 2, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13